SIC
SMMT icon

SJS Investment Consulting’s Summit Therapeutics SMMT Stock Holding History

SJS Investment Consulting’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15 Buy
+1
New +$18 ﹤0.01% 2846
2026
Q1 		– Sell
-1
Closed -$18 – 2563
2025
Q4 		$18 Sell
1
-6
-86% -$113 ﹤0.01% 2068
2025
Q3 		$145 Hold
7
– – ﹤0.01% 1536
2025
Q2 		$149 Sell
7
-6
-46% -$137 ﹤0.01% 1427
2025
Q1 		$251 Buy
+13
New +$261 ﹤0.01% 1415

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

SJS Investment Consulting's SMMT Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 1 share worth $15. The stake represents ﹤0.01% of the portfolio and ranks #2846 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in SMMT as recently as Q4 2025.

SJS Investment Consulting first reported a position in SMMT in Q1 2025 and has held it in 5 quarters since. The position peaked at $251 in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • SJS Investment Consulting held 1 share of Summit Therapeutics worth $15 as of Q2 2026.
  • Summit Therapeutics was a new SJS Investment Consulting position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2846 holding.
  • SJS Investment Consulting first reported a position in Summit Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • SJS Investment Consulting's Summit Therapeutics position peaked at $251 in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.